ATB Antivirals Overview
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
4
ATB Antivirals General Information
Description
Developer of a biotechnology platform intended to offer topical therapeutics for diseases associated with the Human Papillomavirus (HPV). The company focuses on formulating and commercializing topical treatments to address the unmet needs concerning genital warts and premalignant infections caused by HPV, enabling patients to get safe and effective treatment options that can improve their quality of life.
Contact Information
Website
www.atbantivirals.comCorporate Office
- Talvitie 11 as 2
- 20610 Turku
- Finland
Corporate Office
- Talvitie 11 as 2
- 20610 Turku
- Finland
ATB Antivirals Timeline
ATB Antivirals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Accelerator/Incubator | 12-Nov-2026 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC | 28-Nov-2023 | Completed | Pre-Clinical Trials | |||
| 3. Debt - General | 01-Aug-2022 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 16-Jun-2022 | $425K | $425K | Completed | Startup | |
| 1. Accelerator/Incubator | 01-Jan-2020 | Completed | Startup |
ATB Antivirals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ATB Antivirals Patents
ATB Antivirals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020296960-A1 | Pharmaceutical compositions of ovatodiolide and the use thereof | Active | 17-Jun-2019 | ||
| AU-2020296960-B2 | Pharmaceutical compositions of ovatodiolide and the use thereof | Active | 17-Jun-2019 | ||
| CA-3143889-A1 | Pharmaceutical compositions of ovatodiolide and the use thereof | Pending | 17-Jun-2019 | ||
| EP-3983083-A1 | Pharmaceutical compositions of ovatodiolide and the use thereof | Pending | 17-Jun-2019 | ||
| US-12773401-B2 | Pharmaceutical compositions of ovatodiolide and the use thereof | Active | 17-Jun-2019 | A61K31/365 |
ATB Antivirals Signals
ATB Antivirals Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eir Women's Health Accelerator | Accelerator/Incubator | |||
| Metsola Ventures | Venture Capital | Minority | ||
| Monttu Ventures | Venture Capital | Minority | ||
| SPARK Finland | Accelerator/Incubator |
ATB Antivirals FAQs
-
Where is ATB Antivirals headquartered?
ATB Antivirals is headquartered in Turku, Finland.
-
What is the size of ATB Antivirals?
ATB Antivirals has 4 total employees.
-
What industry is ATB Antivirals in?
ATB Antivirals’s primary industry is Drug Discovery.
-
Is ATB Antivirals a private or public company?
ATB Antivirals is a Private company.
-
What is ATB Antivirals’s current revenue?
The current revenue for ATB Antivirals is .
-
How much funding has ATB Antivirals raised over time?
ATB Antivirals has raised $1.77M.
-
Who are ATB Antivirals’s investors?
Eir Women's Health Accelerator, Metsola Ventures, Monttu Ventures, and SPARK Finland have invested in ATB Antivirals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process